Disease-specific induced pluripotent stem (iPS) cells

By In-Hyun Park, Natasha Arora, Hongguang Huo, Nimet Maherali, Tim Ahfeldt, A. Shimamura, M. Lensch, Chad A. Cowan, K. Hochedlinger, George Q. Daley. Cell, 2008

2,162 citations recorded by the source corpus.

Tissue culture of immortal cell strains from diseased patients is an invaluable resource for medical research, but is largely limited to tumor cell lines or transformed derivatives of native tissues. Here we describe the generation of induced pluripotent stem (iPS) cells from patients with a variety of genetic diseases with either Mendelian or complex inheritance that include: adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher disease (GD) type III, Duchenne (DMD) and Becker muscular dystrophy (BMD), Parkinson disease (PD), Huntington disease (HD), juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21 and the carrier state of Lesch-Nyhan syndrome. Such patient-specific stem cells offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby enabling disease investigation and drug development.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d1aee6446762435af8cd89e06d371282cc69ba93

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

Citations in the corpus

Human iPSC-based Modeling of Late-Onset Disease via Progerin-induced Aging (2013, positive): “Fibroblast (Park et al., 2008) and mDA neuron differentiations (Kriks et al., 2011) were performed as previously described.”
Epigenetic reprogramming and induced pluripotency (2009, methodology): “Moreover, human fibroblasts (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007) and keratinocytes (Aasen et al., 2008; Maherali et al., 2008) have been converted into iPS cells using the same, and also using a different combination of factors, including OCT4, SOX2, LIN28 and NANOG (Yu…”
Modeling early retinal development with human embryonic and induced pluripotent stem cells (2009, background): “The potential for iPS cells to generate multiple retinal cell types will aid in the development of in vitro models of human retinal degenerative diseases and stimulate investigation into customized stem cell therapies for patients afflicted by these disorders (34, 35).”
Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. (2010, background): “Human iPSCs also provide a unique platform for studying genetic diseases in vitro (Park et al., 2008).”
Role of the murine reprogramming factors in the induction of pluripotency (2009, neutral): “iPS cells hold great promise for the study and therapy of human diseases (Dimos et al., 2008; Park et al., 2008) because they are highly”
The promise of induced pluripotent stem cells in research and therapy (2012, methodology): “In this assay, the in vivo differentiation potential of human iPS cells is measured after their injection subcutaneously or intramuscularly into immunodeficient mic”
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations (2011, positive): “Human induced pluripotent stem cell (hiPSC) technology, which enables the epigenetic reprogramming of human somatic cells into an embryonic stem cell-like state followed by differentiation into any cell type of the body, is being developed as a key component of such in vitro disease modeling (Dimos ”
Pluripotency: Toward a gold standard for human ES and iPS cells (2009, background): “IPS technology holds enormous promise as it raises the prospect of derivation of disease-specific (Dimos et al., 2008; Park et al., 2008) and, potentially, patient-specific pluripotent cells (Yamanaka, 2007).”